SCHEMBL1630720

SCHEMBL1630720

Cc1ccccc1S(=O)(=O)N(CC(=O)O)c1ccc(Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 3/20 0.58
KEAP1 Q14145 3/20 0.52
NFE2L2 Q16236 3/20 0.52
TSHR P16473 1/20 0.51
MAPT P10636 2/20 0.50
OXTR P30559 2/20 0.48
POLB P06746 2/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NSD2 O96028 1/20 0.45
ESR1 P03372 1/20 0.45
APEX1 P27695 1/20 0.45
RECQL P46063 1/20 0.45
ESR2 Q92731 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
AVPR1A P37288 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL1920216 0.97 HCRTR2 (0.56) HCRTR2KEAP1NFE2L2TSHRMAPT
SCHEMBL6669465 0.90 HCRTR2 (0.61) HCRTR2KEAP1NFE2L2TSHRMAPT
SCHEMBL1040690 0.89 HCRTR2 (0.72) HCRTR2KEAP1NFE2L2TSHRMAPT
SCHEMBL1631672 0.86 HCRTR2 (0.58) HCRTR2KEAP1NFE2L2TSHRMAPT
SCHEMBL1630581 0.84 HCRTR2 (0.56) HCRTR2KEAP1NFE2L2TSHRMAPT
SCHEMBL1920218 0.84 HCRTR2 (0.53) HCRTR2MAPTOXTRMEN1KMT2A
SCHEMBL1629459 0.83 TSHR (0.63) KEAP1NFE2L2TSHRMAPTSMN1; SMN2
SCHEMBL1630305 0.78 KEAP1 (0.71) KEAP1NFE2L2MAPTOXTRMEN1
SCHEMBL1632092 0.78 KEAP1 (0.86) HCRTR2KEAP1NFE2L2MAPTMEN1
SCHEMBL1037307 0.77 HCRTR2 (0.64) HCRTR2KEAP1NFE2L2TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245006-B1 SULFONAMIDES AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-06-01 EP disclosed
EP-2245006-B1 SULFONAMIDES AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-06-01 EP disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
WO-2009092642-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-30 WO disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPSR1 HCRTR2 1/4885KEAP1 1802/4885NFE2L2 1690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.